These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 19841453

  • 1. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.
    Ann Intern Med; 2009 Oct 20; 151(8):517-27. PubMed ID: 19841453
    [Abstract] [Full Text] [Related]

  • 2. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW.
    Lung; 2006 Oct 20; 184(4):217-22. PubMed ID: 17006748
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS.
    Chest; 2007 Dec 20; 132(6):1756-63. PubMed ID: 17951625
    [Abstract] [Full Text] [Related]

  • 4. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.
    Kunz LI, Ten Hacken NH, Lapperre TS, Timens W, Kerstjens HA, van Schadewijk A, Vonk JM, Sont JK, Snoeck-Stroband JB, Postma DS, Sterk PJ, Hiemstra PS, GLUCOLD Study Group.
    Eur Respir J; 2017 Jan 20; 49(1):. PubMed ID: 28049170
    [Abstract] [Full Text] [Related]

  • 5. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
    Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK, SCO30005 Study Group.
    Am J Respir Crit Care Med; 2006 Apr 01; 173(7):736-43. PubMed ID: 16424444
    [Abstract] [Full Text] [Related]

  • 6. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.
    Ann Intern Med; 2007 Apr 17; 146(8):545-55. PubMed ID: 17310045
    [Abstract] [Full Text] [Related]

  • 7. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Rousseau R, ABC (Advair, Biomarkers in COPD) Investigators.
    BMC Pulm Med; 2006 Feb 06; 6():3. PubMed ID: 16460562
    [Abstract] [Full Text] [Related]

  • 8. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
    Clin Ther; 2006 Jan 15; 28(1):73-85. PubMed ID: 16490581
    [Abstract] [Full Text] [Related]

  • 10. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 15; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 11. Summaries for patients. Effect of treatment with fluticasone with and without salmeterol on airway inflammation and lung function in patients with chronic obstructive pulmonary disease: a randomized trial.
    Ann Intern Med; 2009 Oct 20; 151(8):I21. PubMed ID: 19841438
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Additive effects of salmeterol and fluticasone or theophylline in COPD.
    Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S.
    Chest; 2000 Dec 20; 118(6):1576-81. PubMed ID: 11115442
    [Abstract] [Full Text] [Related]

  • 15. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S, Evans DJ, Karner C, Cates CJ.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007033. PubMed ID: 21975759
    [Abstract] [Full Text] [Related]

  • 16. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA, Hawes HG, Doig CJ, Johnson MW, Yokoba M, Wilde ER.
    Chest; 2010 Mar 05; 137(3):558-65. PubMed ID: 19820074
    [Abstract] [Full Text] [Related]

  • 17. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF, Timmer W, Sagkriotis A, Viel K.
    Chest; 2008 Aug 05; 134(2):255-262. PubMed ID: 18403672
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 05; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
    Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T.
    Chest; 2003 Sep 05; 124(3):834-43. PubMed ID: 12970006
    [Abstract] [Full Text] [Related]

  • 20. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ, Postma DS, Klooster K, Lapperre TS, Vonk JM, Sont JK, Kerstjens HAM, Snoeck-Stroband JB, Hiemstra PS, Sterk PJ, GLUCOLD Study GroupDepartment of Pulmonology, LUMC, Leiden, The Netherlands..
    Chest; 2015 Aug 05; 148(2):389-396. PubMed ID: 25836351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.